BIOMAT Database Logo BIOMAT Database Logo

[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma]. 2006

Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Department of Hematology, General Hospital of PLA, Beijing 100853, China.

The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin's lymphoma. Twenty-five patients with refractory or relapsed non-Hodgkin's lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen. The results showed that the complete remission rate was 24.0% (6/25) and the partial remission rate was 28.0%, having an overall response rate of 52%. The median survival duration was 13 months and the median duration of progression-free survival was 8 months. The most frequent complications were gastrointestinal complaint (nausea, vomiting etc.) and myelosuppression. No treatment related mortality was found. It is concluded that the IEMAD (modified MIME) regimen may be a safe and effective regimen that can be used in treatment of patients with refractory or relapsed non-Hodgkin's lymphoma who did not respond to other regimens.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008935 Mitoguazone Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase. Methylglyoxal Bis(guanylhydrazone),MGBG,Methyl-gag,NSC-32946,Methyl gag,Methylgag,NSC 32946,NSC32946
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
October 2002, Journal of Korean medical science,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
November 1987, Oncology (Williston Park, N.Y.),
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
July 2001, Oncology (Williston Park, N.Y.),
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
May 2009, Anticancer research,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
October 2014, Annals of hematology,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy.
October 2015, BMJ clinical evidence,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation.
September 1989, The American journal of medicine,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
December 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
New treatment for relapsed or refractory Hodgkin's lymphoma.
June 2019, The Lancet. Oncology,
Hong-Hua Li, and Xiao-Xiong Wu, and Quan-Shun Wang, and Yu Zhao, and Jian Bo, and Shu-Hong Wang, and Wan-Ming DA, and Li Yu
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
January 2015, Drug design, development and therapy,
Copied contents to your clipboard!